AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMURON LTD

0.031

+0.0013.33%

Volume:120.00K

Turnover:3.72K

Market Cap:10.13M

PE:-1.37

High:0.031

Open:0.031

Low:0.031

Close:0.030

52wk High:0.098

52wk Low:0.030

Shares:326.65M

Float Shares:265.37M

Volume Ratio:0.31

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.023

ROE:-50.21%

ROA:-26.07%

PB:1.25

PE(LYR):-1.37

Loading ...

Overview Company News Filings

BRIEF-Immuron Says Phillip Hains Resigns As CFO

Immuron Ltd-Company Secretary/CFO Appointment/Resignation

THOMSON REUTERS

Immuron Ltd - Mraaron Laurita Appointed as Chief Financial Officer

THOMSON REUTERS

Immuron Ltd - Phillip Hains Resigns as CFO

THOMSON REUTERS

Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference

Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target

BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln

Immuron Limited Reports 5% Increase in Global H1 Sales

Immuron Reports Continued Sales Growth

THOMSON REUTERS

Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference

Immuron Raises A$3.5 Million in Share Sale

Immuron and U.S. Military Secure Department of Defense Grant to Develop Oral Therapeutics for Campylobacter and Shigella

Immuron Ltd - Research Agreement Funded by U.S. Department of Defense Subaward

THOMSON REUTERS

Immuron Ltd - to Produce Two Hyper-Immune Bovine Colostrum Products

THOMSON REUTERS

BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics Development

BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research

Immuron Ltd-U.S. Department of Defense Award & Clinical Trial Update

THOMSON REUTERS

Immuron Limited Announces Director Interest Disclosure Availability

Immuron Says IMM-529 IND Approved By FDA

Immuron Ltd-CEO Address

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.031,"timestamp":1770700320000,"preClose":0.03,"halted":0,"volume":120000,"delay":0,"changeRate":0.03333333333333337,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":326653609,"eps":-0.022586,"marketStatus":"Closed","change":0.001,"latestTime":"02-10 16:12:00 AEDT","open":0.031,"high":0.031,"low":0.031,"amount":3720,"amplitude":0,"askPrice":0.031,"askSize":10000,"bidPrice":0.03,"bidSize":199324,"shortable":3,"etf":0,"ttmEps":-0.022586,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.03,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.308432,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-26.07%","roe":"-50.21%","lyrEps":-0.022586,"volumeRatio":0.308432,"shares":326653609,"dividePrice":0,"high":0.031,"amplitude":0,"preClose":0.03,"low":0.031,"week52Low":0.03,"pbRate":"1.25","psRate":"1.39","week52High":0.098,"institutionHeld":0,"latestPrice":0.031,"committee":0.904454,"eps":-0.022586,"divideRate":0,"volume":120000,"delay":0,"ttmEps":-0.022586,"open":0.031,"prevYearClose":0.036,"prevWeekClose":0.03,"prevMonthClose":0.035,"prevQuarterClose":0.036,"fiveDayClose":0.034,"twentyDayClose":0.034,"sixtyDayClose":0.068},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610450130","title":"BRIEF-Immuron Says Phillip Hains Resigns As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2610450130","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610450130?lang=en_us&edition=fundamental","pubTime":"2026-02-09 09:32","pubTimestamp":1770600730,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Says Phillip Hains Resigns As CFOFeb 9 (Reuters) - Immuron Ltd IMC.AX:COMPANY SECRETARY/CFO APPOINTMENT/RESIGNATIONPHILLIP HAINS RESIGNS AS CFOMR AARON LAURITA APPOINTED AS CHIEF FINANCIAL OFFICERFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUE8N2YXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2610503064","title":"Immuron Ltd-Company Secretary/CFO Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2610503064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610503064?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:26","pubTimestamp":1770593218,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUE8N2YXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2610062503","title":"Immuron Ltd - Mraaron Laurita Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2610062503","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610062503?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:26","pubTimestamp":1770593218,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUE8N2YXK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2610030615","title":"Immuron Ltd - Phillip Hains Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2610030615","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610030615?lang=en_us&edition=fundamental","pubTime":"2026-02-09 07:26","pubTimestamp":1770593218,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nTUE8N2YXK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2606157291","title":"Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2606157291","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606157291?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:51","pubTimestamp":1769410282,"startTime":"0","endTime":"0","summary":"Immuron Limited has published the transcript of its CEO’s presentation at the Emerging Growth Conference, held virtually on January 22, 2026. The event featured Immuron’s Chief Executive Officer, Steven Lydeamore, who addressed investors and stakeholders about the company’s latest advancements. During the call, the CEO highlighted Immuron’s proprietary technology, which utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum to target infectious diseases. “Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by digestive enzymes,” stated the CEO, emphasizing the unique benefits of the company’s orally active antibody therapies. Key developments discussed included the progress of IMM-124E , designed to combat enterotoxigenic Escherichia coli , and ongoing collaborations with Monash University to develop IMM-529 for targeting Clostridioides difficile. The CEO noted, “This unique 3-target approach has yielded prom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9Htw1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2605460193","title":"Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605460193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605460193?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:00","pubTimestamp":1769079651,"startTime":"0","endTime":"0","summary":"Emerging Growth Research has released a Flash Research Update on Immuron Limited , maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2t9Qry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2604139014","title":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604139014","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604139014?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:25","pubTimestamp":1768832724,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 MlnJan 19 (Reuters) - Immuron Ltd IMC.AX:IMMURON REPORTS CONTINUED SALES GROWTHIMMURON LTD - H1 GLOBAL      TRAVELAN SALES AUD$4.2 MILLIONSource text: ID:nGNX6r0VRNFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA8NBSQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2604801571","title":"Immuron Limited Reports 5% Increase in Global H1 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2604801571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604801571?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:00","pubTimestamp":1768820419,"startTime":"0","endTime":"0","summary":"Immuron Limited has reported continued sales growth for the first half  of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period . Second quarter  global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan in Jean Coutu pharmacies in Quebec.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL6pKhxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","NDAQ","SG9999014005.SGD","LU2210149790.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","BK7508","BK4585","BK4588","IE00B3QW5Z07.USD","BK7067","IMC.AU","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD"],"gpt_icon":0},{"id":"2604180611","title":"Immuron Reports Continued Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2604180611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604180611?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:00","pubTimestamp":1768820400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA8NBSQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2603616642","title":"Immuron CEO Steven Lydeamore to Present at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603616642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603616642?lang=en_us&edition=fundamental","pubTime":"2026-01-14 21:01","pubTimestamp":1768395660,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced that its Chief Executive Officer, Steven Lydeamore, will present virtually at the Emerging Growth Conference on Thursday, January 22, 2026, from 2:40pm to 2:50pm U.S. Eastern Time. An archived webcast of the presentation will be made available after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL5v7cjF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2590586402","title":"Immuron Raises A$3.5 Million in Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590586402","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590586402?lang=en_us&edition=fundamental","pubTime":"2025-12-10 19:03","pubTimestamp":1765364621,"startTime":"0","endTime":"0","summary":"Immuron Limited announced that it has issued 45.472 million shares at A$0.07910 per share, raising A$3.5 million. This capital raising has exhausted the company's At-The-Market Facility. The funds will be allocated toward advancing Immuron's objectives, including ongoing clinical and research initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL2y15SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2588102930","title":"Immuron and U.S. Military Secure Department of Defense Grant to Develop Oral Therapeutics for Campylobacter and Shigella","url":"https://stock-news.laohu8.com/highlight/detail?id=2588102930","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588102930?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:00","pubTimestamp":1764759624,"startTime":"0","endTime":"0","summary":"Immuron Limited has announced a new research agreement funded by a U.S. Department of Defense subaward, in collaboration with the Naval Medical Research Command  and the Walter Reed Army Institute of Research . The grant supports the development of two new oral therapeutics targeting Campylobacter and Shigella. This project involves multiple organizations, including Immuron, NMRC, and WRAIR, and aims to produce hyper-immune bovine colostrum products for pre-clinical evaluation, specifically designed for the U.S. military.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via GlobeNewswire  on December 03, 2025, and is solely responsible for the information con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2fSV8v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK7508","BK4585","IMC.AU","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4588","BK7067","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588401027","title":"Immuron Ltd - Research Agreement Funded by U.S. Department of Defense Subaward","url":"https://stock-news.laohu8.com/highlight/detail?id=2588401027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588401027?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:00","pubTimestamp":1764759600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA9PVPSY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2588010272","title":"Immuron Ltd - to Produce Two Hyper-Immune Bovine Colostrum Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2588010272","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588010272?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:00","pubTimestamp":1764759600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA9PVPSY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2588097947","title":"BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588097947","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588097947?lang=en_us&edition=fundamental","pubTime":"2025-12-03 14:01","pubTimestamp":1764741675,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Receives US Department Of Defense Award For Oral Therapeutics DevelopmentDec 3  - Immuron Ltd IMC.AX:U.S. DEPARTMENT OF DEFENSE AWARD & CLINICAL TRIAL UPDATERECEIVES US DEPARTMENT OF DEFENSE AWARD FOR ORAL THERAPEUTICS DEVELOPMENTFurther company coverage: IMC.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUE8PBT9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2588091452","title":"BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research","url":"https://stock-news.laohu8.com/highlight/detail?id=2588091452","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588091452?lang=en_us&edition=fundamental","pubTime":"2025-12-03 12:02","pubTimestamp":1764734555,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron hits near 1-month high on US Defense-funded research** Shares of Australia's Immuron IMC.AX rise as much as 12.1% to A$0.074, their highest since November 5** Biopharmaceutica","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X908E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2588093123","title":"Immuron Ltd-U.S. Department of Defense Award & Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2588093123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588093123?lang=en_us&edition=fundamental","pubTime":"2025-12-03 09:40","pubTimestamp":1764726029,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUE8PBT9D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2585259921","title":"Immuron Limited Announces Director Interest Disclosure Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2585259921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585259921?lang=en_us&edition=fundamental","pubTime":"2025-11-22 04:51","pubTimestamp":1763758275,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL5ySGQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Immuron Limited Announces Director Interest Disclosure Availability","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2584926851","title":"Immuron Says IMM-529 IND Approved By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926851","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926851?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570297,"startTime":"0","endTime":"0","summary":"Nov 5 (Reuters) - Immuron Ltd ::*IMM-529 IND APPROVED BY FDA*Further company coverage: IMC.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202511:12:18.977 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD88gNP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2582897033","title":"Immuron Ltd-CEO Address","url":"https://stock-news.laohu8.com/highlight/detail?id=2582897033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582897033?lang=en_us&edition=fundamental","pubTime":"2025-11-11 07:37","pubTimestamp":1762817844,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUE7FMF2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}